These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 19010910)

  • 1. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
    Schmelz K; Wagner M; Dörken B; Tamm I
    Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
    Al-Salihi M; Yu M; Burnett DM; Alexander A; Samlowski WE; Fitzpatrick FA
    Epigenetics; 2011 Aug; 6(8):1021-8. PubMed ID: 21725200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells.
    Vispé S; Deroide A; Davoine E; Desjobert C; Lestienne F; Fournier L; Novosad N; Bréand S; Besse J; Busato F; Tost J; De Vries L; Cussac D; Riond J; Arimondo PB
    Oncotarget; 2015 Jun; 6(17):15265-82. PubMed ID: 25948775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of demethylating agents in hematology.
    Navada SC; Steinmann J; Lübbert M; Silverman LR
    J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
    Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
    Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
    Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
    Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
    Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K
    Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
    Lund K; Cole JJ; VanderKraats ND; McBryan T; Pchelintsev NA; Clark W; Copland M; Edwards JR; Adams PD
    Genome Biol; 2014 Aug; 15(8):406. PubMed ID: 25315154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.
    Karpf AR; Moore BC; Ririe TO; Jones DA
    Mol Pharmacol; 2001 Apr; 59(4):751-7. PubMed ID: 11259619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
    Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
    BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
    Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
    Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.
    Tanaka H; Arakawa H; Yamaguchi T; Shiraishi K; Fukuda S; Matsui K; Takei Y; Nakamura Y
    Nature; 2000 Mar; 404(6773):42-9. PubMed ID: 10716435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
    Gray SG; Baird AM; O'Kelly F; Nikolaidis G; Almgren M; Meunier A; Dockry E; Hollywood D; Ekström TJ; Perry AS; O'Byrne KJ
    Int J Mol Med; 2012 Dec; 30(6):1505-11. PubMed ID: 23007409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
    Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
    Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
    Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
    Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
    Bryan J; Kantarjian H; Garcia-Manero G; Jabbour E
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):661-72. PubMed ID: 21500965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.
    Thudium KE; Ghoshal S; Fetterly GJ; Haese JP; Karpf AR; Wetzler M
    Leuk Res; 2012 Nov; 36(11):1410-6. PubMed ID: 22884950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.